Kymera Therapeutics (KYMR) Citi's Biopharma Back to School Conference summary

Platform evolution and innovation

• Focus shifted to immunology over the past five years, leveraging validated pathways and unmet needs.

• Platform advancements enable targeting previously undruggable proteins with high specificity and oral bioavailability.

• Integration of AI and machine learning aids in target identification, scaffold design, and biomarker discovery.

• Second-generation degraders like KT-621 and KT-579 show improved potency and clinical translation compared to earlier programs.

• Continuous innovation is emphasized to maintain leadership in targeted protein degradation.

STAT6 program and clinical development

• KT-621, a first-in-class STAT6 degrader, blocks both IL-4 and IL-13, aiming for biologics-like efficacy with oral dosing.

• Phase I-B in atopic dermatitis (AD) patients focuses on translating robust STAT6 degradation and biomarker effects from healthy volunteers.

• Phase II studies in AD and asthma will use dose-ranging, double-blind, placebo-controlled designs to correlate degradation with clinical outcomes.

• STAT6 degradation above 90% achieved at low doses, with consistent effects across blood and skin.

• Additional dosing arms in phase I-B enhance confidence in phase II-B dose selection, with no safety-driven changes.

Biomarkers, patient selection, and trial design

• Biomarker analysis includes Th2 cytokines, TARC, Eotaxin-3, and skin transcriptomics to compare with dupilumab effects.

• Standard eligibility criteria (EASI, vIGA, BSA, pruritus) ensure selection of moderate to severe AD patients.

• Placebo effect minimized through rigorous protocol, experienced site selection, and active oversight.

• Comprehensive data sharing planned, including degradation profiles, biomarkers, and efficacy endpoints.